Bipolar Disorder Research

The Mood and Anxiety Disorders Program (MAP) is working to advance a range of new treatments for bipolar disorder. Our pharmaceutical studies include research to find new uses for existing medications such as minocycline (an FDA-approved antibiotic with promising antidepressant effects in bipolar cases) and to design new drugs. We are also studying more effective ways to use device-based therapies including Transcranial Magnetic Stimulation (TMS), in which a magnetic coil is placed against the forehead to stimulate nerves in the brain.

In addition to studying new treatments, MAP is using neuroimaging such as functional MRI (fMRI) to investigate brain activity during bipolar disorder in order to better understand the causes of this condition.

Clinical Trials for Bipolar Disorder

MAP is currently seeking individuals interested in participating in the following clinical trials for bipolar disorder.

  • Deep Brain TMS for Bipolar Depression: Evaluates the efficacy and safety of H1-Coil deep brain rTMS (dTMS) in subjects with bipolar depression who are taking mood stabilizers and were previously unsuccessfully treated with antidepressant medications.

To participate in one of our clinical trials for Mood and Anxiety Disorders or to learn more about eligibility, please contact Katie Huryk (212-241-3089, kathryn.huryk@mssm.edu).


Contact Us

Tel: 212-241-7906
Fax: 212-241-3354
Send e-mail

Atran Berg Laboratory Building
Floor E Level
1428 Madison Avenue
New York, NY 10029  Map

Participate in Bipolar Disorder Clinical Trials

If you are interested in participating, see our current list of clinical trials.